<DOC>
	<DOCNO>NCT00495274</DOCNO>
	<brief_summary>The purpose study select formulation optimal pharmacokinetic profile hypnotic drug develop market .</brief_summary>
	<brief_title>Bioequivalence Food Effect Study Healthy Volunteers</brief_title>
	<detailed_description>A single-centre , open-label , randomize , single-dose , 6-way crossover study investigate pharmacokinetics , safety tolerability 6 different formulation SB-649868 30 mg ( Part A ) effect food select formulation SB-649868 pharmacokinetic ( Part B ) healthy male volunteer</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion criterion : Healthy adult male subject age 18 65 year age inclusive . Body weight BMI within protocol range . Healthy determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . Circulating level LH , FSH testosterone within normal reference range . Signed date write informed consent . The subject able understand comply protocol requirement , instruction protocolstated restriction . Exclusion criterion : Positive prestudy urine drug screen alcohol breath test . Positive prestudy Hepatitis B surface antigen , Hepatitis C antibody , HIV Â½ result . Abuse alcohol per protocol criterion . Consumption prohibit food drink per protocol . Subject prepared eat standard meal provide site . Use prescription nonprescription drug 1 2 week first dose study medication . Where participation study would result donation blood excess 500mL within 56 day period . History presence allergy study drug drug class , history allergy . Smoking history last three month per protocol . An unwillingness male subject follow contraception method per protocol . History presence significant psychiatric , respiratory gastrointestinal illness , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . The subject unable unwilling abstain strenuous physical activity 48 hour screen 48 hour 48 hour treatment period . Current previous ( within 6 month ) participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bioequivalent</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>Reference formulation</keyword>
	<keyword>5 new formulation</keyword>
	<keyword>Food effect</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>